The Handoff: Your Week in Neurology News - 1/26/17

Share this content:

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, the pharmaceutical industry, and the overall state of health care as it affects neurologists.

— One Washington city is trying to tackle the opioid crisis — by suing the pharmaceutical company that makes them.  

— The FDA has given the "OK" to a generic formulation of Jazz Pharma's narcolepsy drug, Xyrem. 

— The first MRI-guided laser ablation surgery in a patient with mesial temporal lobe epilepsy has been completed as part of the ongoing SLATE trial.

— Tau pathology may be the reason why so many patients with Alzheimer's dementia tend to wander

— Takeda and Ovid Therapeutics are collaborating to help advance Takeda's investigational drug for rare pediatric epilepsies. 

— Famed painter Jackson Pollack's works of art are made up of mathematical patterns that are soothing to the brain. 

— The NINDS has announced the 30 award winners of its inaugural R35 Research Program Award, which will fund research initiatives for at least 5 years. The winners' research focuses on neurodegenerative diseases, neural repair, pain mechanisms, and more. 

— The US FDA has approved Teva's abuse-deterrent opioid Vantrela ER.

— In an effort to quell a growing distaste with the industry, the Pharmaceutical Research and Manufacturers of America, a major industry lobbying group, has launched an ad campaign to help improve the image of pharmaceutical companies and their research. Watch the first ad in the "Go Boldy" campaign below.

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus